Delivery of neurotrophic factors and therapeutic proteins for retinal diseases

Bibliography

• IRONS-GEORGES T, CARSON C: Magill's Medical Guide. Revised Edition. Irons-Georges T, Carson C (Eds), Salem Press, Hackensack, NJ, USA (1998).
   Google Scholar
• BLAAUWGEERS H, HOLTKAMP G, RUTTEN H et al.: Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am. J. Pathol (1999) 155:421–428.
   PubMed Web of Science ®Google Scholar
• WEN R, SONG Y, CHENG T et al.: Injury-induced upregulation of bEGF and CNTF mRNAS in the rat retina. J. Neurosci. (1995) 15:7377–7385.
   PubMed Web of Science ®Google Scholar
• ••Study on the upregulation of neurotrophicfactors following injury.
   Google Scholar
• MACHIDA S, CHAUDHRY P, SHINOHARA T et al.: Lens epithelium-derived growth factor promotes photoreceptor survival in light-damaged and RCS rats. Invest. Ophthalmol. Vis. Sci. (2001) 42:1087–1095.
   PubMed Web of Science ®Google Scholar
• WEN R, CHEN T, SONG Y et ell.: Continuous exposure to bright light upregulates bEGF and CNTF expression in the rat retina. Curr. Eye Res. (1998) 17:494–500.
   Google Scholar
• LAVAIL M, UNOKI K, YASUMURA D et al.: Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl Acad. Sci. USA (1992) 89:11249–11253.
   PubMed Web of Science ®Google Scholar
• ••Survey of various neurotrophic factors inanimal models of retinal degeneration.
   Google Scholar
• SCHINDLER C: Series introduction. JAK-STAT signaling in human disease. Clin. Invest. (2002) 109:1133–1137.
   PubMed Web of Science ®Google Scholar
• MANTHORPE M, SKAPER S, ADLER Ret at.: Cholinergic neuronotrophic factors: fractionation properties of an extract from selected chick embryonic eye tissues. Neurochem. (1980) 34:69–75.
   Google Scholar
• SENDTNER M, KREUTZBERG G, THOENEN H: Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature (1990) 345:440–441.
   PubMed Web of Science ®Google Scholar
• MATA M, JIN C, FINK D: Axotomy increases CNTF receptor mRNA in rat spinal cord. Brain Res. (1993) 610:162–165.
   PubMed Web of Science ®Google Scholar
• CLATTERBUCK R, PRICE D, KOLIATSOS V: Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. Proc. Natl Acad. Sci. USA (1993) 90:2222–2226.
   PubMed Web of Science ®Google Scholar
• MEY J, THANOS S: Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. (1993) 602:304–317.
   PubMed Web of Science ®Google Scholar
• •Intravitreal neurotrophic factor administration provides axonal support.
   Google Scholar
• CUI Q, LU Q, SO K et al.: CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest. OphthalmoL Vis. Sci. (1999) 40:760–766.
   PubMed Web of Science ®Google Scholar
• LAVAIL M, YASUMURA D, MATTHES M et al.: Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. OphthalmoL Vis. Sci. (1998) 39:592–602.
   PubMed Web of Science ®Google Scholar
• •Mouse models of retinal degeneration and neurotrophic-mediated photoreceptor rescue.
   Google Scholar
• LIANG F, DEJNEKA N, COHEN D et ell.: AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mo/. Ther. (2001) 3:241–248.
   Google Scholar
• CHONG N, ALEXANDER R, WATERS Let al.: Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. Invest. OphthalmoL Ws. Sci. (1999) 40:1298–1305.
   Google Scholar
• LINDSAY R, BARDE Y, DAVIES A et al.: Differences and similarities in the neurotrophic growth factor requirements of sensory neurons derived from neural crest and neural placode. J. Cell. Sci. Suppl. (1985) 3:115–129.
   PubMedGoogle Scholar
• LINDSAY R, THOENEN H, BARDE Y: Placode and neural crest-derived sensory neurons are responsive at early developmental stages to brain-derived neurotrophic factor. Dev. Biol. (1985) 112:319–328.
   PubMed Web of Science ®Google Scholar
• DAVIES A, THOENEN H, BARDE Y: The response of chick sensory neurons to brain-derived neurotrophic factor. Neurosci. (1986) 6:1897–1904.
   PubMed Web of Science ®Google Scholar
• JOHNSON J, BARDE Y, SCHWAB M et al.: Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J. Neurosci. (1986) 6:1897–1904.
   PubMedGoogle Scholar
• GAO H, QIAO X, HEFTI F et al.: Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury. Invest. OphthalmoL Ws. Sci. (1997) 38:1840–1847.
   PubMed Web of Science ®Google Scholar
• HACKETT S, SCHOENFELD C, FREUND J et al.: Neurotrophic factors, cytokines and stress increase expression of basic fibroblast growth factor in retinal pigmented epithelial cells. Exp. Eye Res. (1997) 64:865–873.
   PubMed Web of Science ®Google Scholar
• DIPOLO A, AIGNER L, DUNN R et aL: Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Natl. Acad. Sci. USA (1998) 95:3978–3983.
   PubMed Web of Science ®Google Scholar
• IKEDA K, TANIHARA H, HONDA Y et al.: BDNF attenuates retinal cell death caused by chemically induced hypoxia in rats. Invest. OphthalmoL Vis. Sci. (1999) 40:2130–2140.
   PubMed Web of Science ®Google Scholar
• OKOYE G, ZIMMER J, SUNG J et aL: Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J. Neurosci. (2003) 23:4164–4172.
   PubMed Web of Science ®Google Scholar
• •BDNF is neuroprotective in animal models of retinal degeneration.
   Google Scholar
• AIRAKSINEN M, SAARMA M: The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. (2002) 3:383–394.
   PubMed Web of Science ®Google Scholar
• JOHANSSON M, FRIEDEMANN M, HOFFER B et al.: Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp. NeuroL (1995) 134:25–34.
   PubMed Web of Science ®Google Scholar
• STROMBERG I, BJORKLUND L, JOHANSSON M et al.: Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp. NeuroL (1993) 124:401–402.
   PubMed Web of Science ®Google Scholar
• KLOCKER N, BRAUNLING F, ISENMANN S et al.: In vivo neurotrophic effects of GDNF on axotomized retinal ganglion cells. Neuroreport (1997) 8:3439–3442.
   PubMed Web of Science ®Google Scholar
• FRASSON M, PICAUD S, LEVEILLARD T et al.: Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Invest. OphthalmoL Vis. SGT. (1999) 40:2724–2734.
   PubMed Web of Science ®Google Scholar
• •GDNF is neuroprotective in the rd/rd mouse.
   Google Scholar
• MCGEE-SANFTNER L, ABEL H, HAUSWIRTH WW, FLANNERY JG: Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mot Ther. (2001) 4:622–629.
   PubMed Web of Science ®Google Scholar
• WU W, LAI C, CHEN S et ell.: GDNF gene therapy attenuates retinal ischemic injuries in rats. Mot Vis. (2004) 10:93–102.
   Google Scholar
• MIYAZAKI M, IKEDA Y, YONEMITSU Yet al.: Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats. Gene Ther. (2003) 10:1503–1511.
   Google Scholar
• HOLEKAMP N, BOUCK N, VOLPERT 0: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. OphthalmoL (2002) 134:220–227.
   PubMed Web of Science ®Google Scholar
• APTE R, BARREIRO R, DUH E et aL: Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest. Ophthalmol. Vis. Sci. (2004) 45:4491–4497.
   PubMed Web of Science ®Google Scholar
• PRESTA L, CHEN H, O'CONNOR S: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
   PubMed Web of Science ®Google Scholar
• BOUGHMAN J, CONNEALLY P, NANCE W: Population genetic studies of retinitis pigmentosa. Am. J. Hum. Genet. (1980) 32:223–235.
   PubMed Web of Science ®Google Scholar
• FARRAR G, KENNA P, HUMPHRIES P: On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J. (2002) 21:857–864.
   PubMed Web of Science ®Google Scholar
• DITTRICH F, THOENEN H, SENDTNER M: Ciliary neurotrophic factor: pharmacokinetics and the acute-phase response in the rat. Ann. Neurol. (1994) 35:151–163.
   PubMed Web of Science ®Google Scholar
• TAN S, DEGLON N, ZURN A: Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell. Transplant. (1996) 5:577–587.
   PubMed Web of Science ®Google Scholar
• CEDARBAUM J, CHAPMAN C, CHARATAN M: The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. Clin. NeuropharmacoL (1995) 18:500–514.
   PubMed Web of Science ®Google Scholar
• HERRERO-VANRELL R, REFOJO M: Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug. Deliv. Rev. (2001) 52:5–16.
   PubMed Web of Science ®Google Scholar
• MARTIN D, DUNN J, DAVIS J: Use ofthe ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am. J. Ophthalmol. (1999) 127:329–339.
   PubMed Web of Science ®Google Scholar
• YASUKAWA T, KIMURA H, KUNOU N: Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch. Clin. Exp. Ophthalmol. (2000) 238:186–190.
   PubMed Web of Science ®Google Scholar
• GEROSKI D, EDELHAUSER H: Transscleral drug delivery for posterior segment disease. Adv. Drug. Deliv. Rev. (2001) 52:37–48.
   PubMed Web of Science ®Google Scholar
• TAO W, WEN R, GODDARD M et al.: Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. (2002) 43:3292–3298.
   PubMed Web of Science ®Google Scholar
• •Encapsulated cell therapy-mediated CNTF delivery is therapeutic in several animal models of RP.
   Google Scholar
• THANOS C, BELL W O'ROURKE P et al.: Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng. (2004) 10:1617–1622.
   Google Scholar
• SIEVING P, CARUSO R, TAO W et al.:Phase I study of ciliary neurotrophic factor (CNF) delivered by intravitreal implant of encapsulated cell technology (ECT) device in patients with retinitis pigmentosa. 2005 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA (1–5 May 2005).
   Google Scholar
• VANWIJNGAARDEN P, COSTER D, WILLIAMS K: Inhibitors of ocular neovascularization: promises and potential problems. JAMA (2005) 293:1509–1513.
   PubMed Web of Science ®Google Scholar
• GRAGOUDAS E, ADAMIS A, CUNNINGHAM E et al.: Pegaptanib for neovascular age-related macular degeneration. N Engl. J. Med. (2004) 351:2805–2816.
   PubMed Web of Science ®Google Scholar
• DUH E, YANG H, ISUZUMA et al.: Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. (2002) 43:821–829.
   PubMed Web of Science ®Google Scholar
• GEHLBACH P, DEMETRIADES A, YAMAMOTO S et al.: Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. (2003) 10:637–646.
   PubMed Web of Science ®Google Scholar
• MORI K, GEHLBACH P, ANDO A et al.:Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. (2002) 43:2428–2434.
   PubMed Web of Science ®Google Scholar
• MORI K, GEHLBACH P, YAMAMOTO S et al.: AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2002) 43:1994–2000.
   PubMed Web of Science ®Google Scholar
• ••Efficacy of AAV-mediated PEDF deliveryin an animal model of exudative AMD.
   Google Scholar
• SAISHIN Y, SILVA R, SAISHIN Yet al.:Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum. Gene Ther. (2005) 16:473–478.
   Google Scholar
• http://www.mdsupport.org/library/ numbers.html Macular Degeneration Support Website, 2005.
   Google Scholar
• http://www.neurotechusa.com/ news_press_050105.asp Neurotech USA. Website Press Release, 2005.
   Google Scholar
• http://www.genvec.com/ go.cfm?do=Press.View&prid=75 Genvec Website Press Release, 2002.
   Google Scholar
• http://www.genvec.com/ go.cfm?do=Press.View&prid=23 Genvec Website Press Release, 2004.
   Google Scholar
• http://webvision.med.utah.edu University of Utah, Webvision.
   Google Scholar